The Center for Health Market Innovations (CHMI) has compiled profiles on over 1,200 programs and counting. For TB innovations, the CHMI database contains 58 programs that work on TB in 33 countries.
To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.
World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Included is a list of publications, news items, events, and links related to TB and World TB Day 2013.
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Included are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
The WHO released the Global Tuberculosis Report 2012 today. The main highlights and additional coverage are included.
The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the Millennium Development Goals (MDGs).
We will have our 2012 Annual Meeting in Kuala, Lumpur on Wednesday, November 14 at the Impiana KLCC Hotel from 13:00 to 17:30. The meeting will be held in conjunction with the 43rd Union World Conference on Lung Health.
TB REACH is currently accepting applications for Wave 3. The deadline for submitting proposals for Wave 3 is 17 September 2012.
The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert and 2. Dramatic results from TB REACH mHealth project make case for wider implementation.
For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.